Yüklüyor......
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma
The management of advanced renal cell carcinoma (RCC) has dramatically changed over the past decade. Therapies that target the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways have considerably expanded treatment options; however, most patients with advance...
Kaydedildi:
| Yayımlandı: | Nat Rev Urol |
|---|---|
| Asıl Yazarlar: | , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2016
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5532875/ https://ncbi.nlm.nih.gov/pubmed/27324121 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nrurol.2016.103 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|